Dengue Cases Soar in 2024 as 5 Billion may Face Arbovirus Risk by 2050

Approximately four billion individuals globally are in danger of arbovirus infections, with projections showing this number will rise to 5 billion by 2050. Dengue cases have increased in all six WHO regions, with the number of cases nearly...

Recipharm Bolsters pharma development capabilities with strategic funding

Recipharm, a top global pharmaceutical CDMO, is enhancing its pharmaceutical development abilities by making strategic investments and incorporating advanced technologies. This investment enhances its offerings for both early and late-stage...

Liquidia and Pharmosa Biopharm Team up to develop inhaled treprostinil

Liquidia Corporation and Pharmosa Biopharm have updated their exclusive licensing agreement for L606, an inhaled, sustained-release treprostinil formulation. The drug is currently in a clinical trial for treating pulmonary arterial hypertension...

Emcure Pharma and Gilead Sciences Team up to produce HIV prevention drug

Emcure Pharmaceuticals announced a royalty-free voluntary licensing agreement with Gilead Sciences Ireland UC, a subsidiary of the California-based Gilead Sciences, to manufacture and supply generic versions of lenacapavir, the antiretroviral...

Sapience Therapeutics Initiates patient enrolment in phase 2 study

Sapience Therapeutics, Inc., a biotechnology company in the clinical stage, has reported the enrollment of the initial patient in its phase 2 dose expansion study for ST316, the company's innovative antagonist of b-catenin. The study's phase 1...

Merck Concludes Acquisition of investigational B-cell Depletion Therapy

Merck, also recognized as MSD in countries other than the United States and Canada, revealed the finalization of the acquisition of CN201 from Curon Biopharmaceutical (Curon), a new experimental bispecific antibody in clinical development for...

CCI Approves Rs 13,630-cr Mankind Pharma-Bharat Serums Vaccines deal

The Competition Commission of India (CCI) gave approval to Mankind Pharma's acquisition of Bharat Serums and Vaccines for Rs 13,630 crore. Mankind Pharma, a publicly traded company, is involved in creating, producing, and selling a wide variety of...

Sun Pharma and Philogen Ink Pact to commercialise speciality cancer drug

Sun Pharma announced that they have signed a worldwide licensing deal to market Philogen's specialty anti-cancer immunotherapy Fibromun (L19TNF) from Switzerland and Italy. bPhilogen is conducting registration trials for Fibromun to treat soft...

Genentech to Acquire CDK Inhibitors to treat breast cancer

Regor Pharmaceuticals (USA), a branch of Regor Therapeutics Group, a biotech company in the clinical testing phase, has agreed to a deal where Genentech, part of the Roche Group, will buy a set of advanced CDK inhibitors from Regor to treat breast...

Venus Remedies Receives Market Authorisations for two cancer drugs

Venus Remedies Ltd, a leading pharmaceutical company, announced that it has obtained approvals to market two important oncology medications (carboplatin and bortezomib) in Morocco and the Philippines. "These approvals are pivotal in our...

© 2024 India Pharma Outlook. All Rights Reserved.